邢唷>? ?欹 ?bjbj,(,( 劈NBNBn 8> ,豩6:p"mmmhhhhhhh,攋FmjAhQmmmmmAh?抙???m h?mh??b4踘0矄洦#(vGd>g╤0豩卍V癿?癿|踘?踘$mmmAhAh?mmm豩癿mmmmmmmmm" :  Curriculum VitaeJohn D. Crispino, PhD, MBAPersonal Info: Northwestern University Feinberg School of Medicine Department of Medicine Division of Hematology/Oncology 303 E. Superior Street, Lurie 5-113 Chicago, IL 60611 Phone: (312) 503-1504 Fax: (312) 503-0189 Email:  HYPERLINK "mailto:j-crispino@northwestern.edu" j-crispino@northwestern.eduEducation 1990 Washington University, A.B. Biology, Magna Cum Laude, Phi Beta Kappa 1996 Massachusetts Institute of Technology, Ph.D. BiologyDissertation Title: The Role of U1 snRNP in Pre-mRNA SplicingThesis Advisor: Dr. Phillip A. Sharp, Nobel Laureate in Medicine 2011 Kellogg School of Management, MBA Majors in Management & Organizations and Finance Post-doctoral Research Training 1996-2000 Fellow with Dr. Stuart H. Orkin, Children抯 Hospital Boston and Harvard Medical SchoolFaculty Appointments 2000-2006 Assistant Professor, Ben May Institute for Cancer Research 2000-2006 Investigator, University of Chicago Cancer Research Center2005-2006 Co-leader, Program in Cancer Molecular Genetics and Hematopoiesis, University of Chicago Cancer Research Center, Chicago, IL2006-2011 Associate Professor with tenure, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 2006-present Investigator, Robert H. Lurie Cancer Center, Northwestern University 2009-present Associate Director of Education and Training, Robert H. Lurie Cancer Center Northwestern University 2009-present Member, Children抯 Memorial Research Center 2011-present Professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 2012-present The Robert I. Lurie, MD and Lora S. Lurie Professor, Division of Hematology/Oncology, Department of Medicine Northwestern University Feinberg School of Medicine, Chicago, IL Administrative Appointments 2009-present Associate Director of Education and Training, Robert H. Lurie Cancer Center Northwestern UniversityCommittee Service University of Chicago 2001 Molecular Biosciences Admission Committee 2001-2004 IACUC Member 2001 Cancer Biology Retreat Committee 2001-2003 Dean's Search Committee for Animal Resources Director2002 Cancer Biology Retreat Committee2002-2006 Cancer Biology Curriculum Committee2002-2006 Molecular Genetics and Cellular Biology Training Grant Steering Committee2003 Cancer Biology Retreat Committee2003 Cancer Biology Seminar Series Committee2003 Ben May Faculty Search Committee2003 Ben May Symposium Organizing Committee 2003-2006 College Council Member2003-2005 BSD Core Facilities Steering Committee 2004 Vice Chair, IACUC2004-2006 ARC Faculty Advisory Committee2004 Cancer Biology Retreat Committee 2004-2006 Herbert Abelson Chair Faculty Search Committee 2005 Molecular Biosciences Admission Committee 2005 Chair, Cancer Biology Retreat Committee 2006 Chair, Developmental Biology Admission Committee 2006 Chair, Cancer Biology Retreat Committee 2006 Developmental Biology Executive Committee2006-2008 Organizer, Chicago Area Hematopoiesis and Leukemia Group Northwestern University 2007-present Organizer, Tumor Cell Biology Seminar Series2007-2010 Institutional Review Board (IRB), Panel D 2007-present FSM Core Committee2007-2008 DOM Mentoring Committee 2008-present Transgenic Core Oversight Committee2009-2010 Stem Cell Core Facility Oversight Committee2009-present Driskill Graduate Program (DGP) Program Committee2009 Organizer, Mini-Symposium on Stem Cell Biology and Regenerative Medicine2010 NU Office of Research Life Sciences Advisory Board Member2010-present Director, Northwestern Stem Cell Core Facility 2010-present Co-director, Cancer Biology Cluster2010-present Co-PI, Carcinogenesis T32 Training Grant 2011-present Research Council, Department of Medicine2011-present Administrative Board of the Graduate SchoolAwards, Honors, Distinctions 1989 Sigma Xi Research Grant 1990 Phi Beta Kappa 1990 Biology Undergraduate Honors, Washington University 1990-1993 NIH Pre-doctoral training grant 1996 Elected to Sigma Xi, national scientific honor society 1996-1999 Jane Coffin Childs Fund for Medical Research Fellow 2000 Special Fellow of the Leukemia and Lymphoma Society 2000-2003 Burroughs Wellcome Career Development in the Biological Sciences Award 2001 Cancer Research Foundation Young Investigator Award 2001 The V Foundation, "V Scholar" Award 2001 American Society of Hematology, Junior Faculty Award 2005 Leukemia and Lymphoma Society Scholar Award 2011 Pamela B. Katten Memorial 2011 Leukemia Researcher of the YearProfessional Society Memberships 1991-present American Society for the Advancement of Science 1999-present American Society of Hematology 2003-present Children's Oncology Group (COG) 2008-present Eastern Cooperative Oncology Group (ECOG) 2006-2009 American Society of Hematology Scientific Subcommittee on Myeloid Neoplasia 2008-2011 ECOG Leukemia Laboratory Committee 2008-2009 COG Myeloid Biology Laboratory Committee 2010-present American Society of Hematology Committee on Investments and Audit Professional and Scientific Service 2003-present Member, Leukemia Research Foundation Medical Advisory Board 2007-2009 Vice Chair, Leukemia Research Foundation Medical Advisory Board 2007-present Editorial Board Member, Blood 2009-present Chair, Leukemia Research Foundation Medical Advisory Board 2009-present Scientific Advisor, the Myeloproliferative Neoplasms Research Foundation 2009-2013 Chartered Member, NIH Molecular and Cellular Hematology Study Section 2010-present Editorial Board Member, Blood Cancer Journal Ad hoc reviewer for the following granting agencies and foundations: NIH Challenge Grant Reviewer (2009)DOD PRMPRP Blood Cancer Panel C (2009)NIDDK Ad hoc PO1 review (2007, 2008, 2009) NIDDK SEP R01 review (2007, 2008, 2009) NIDDK conference grant review (2009) NHLBI Conference Grant Review (2011) The MPD/ MPN Research Foundation (2008-present) Kay Kendall Foundation (UK) 2002-present NIH Hematopoiesis Study Section Ad hoc (2004, 2006, 2007) German Research Foundation (clinical trial review) 2006 Canadian Institute of Health Research (Clinician Scientist Award) 2004 Cancer Research UK (Clinical Research Training Fellowship) 2004 Sick Kids Foundation (Canada) 2003 The Physicians Services (Canada) 2002NIDDK Merit Award Application review (2002)Ad hoc Reviewer for the following journals (partial list): Nature Genetics, Cancer Cell, Genes and Development, Molecular Cell, PLoS Biology, PNAS, Journal of Experimental Medicine, Journal of Clinical Investigation, Blood, Molecular and Cellular Biology, Journal of Biological Chemistry, Experimental Hematology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, Leukemia Research, Leukemia, Thrombosis and Haemostasis, British Journal of Haematology Abstract Reviewer and Session Chair, American Society of Hematology Annual Meeting 2005 Abstract Reviewer, American Society of Hematology Annual Meeting 2007 Coordinating Abstract Reviewer, ASH Annual Meeting 2008 Abstract Reviewer and Session Chair, American Society of Hematology Annual Meeting 2011 Coordinating Abstract Reviewer, American Association of Cancer Research, Annual Meeting 2012 Teaching Experience and ActivitiesFormal Coursework University of Chicago Date Title of Course Course Number Contact Hours 2001 Topics in Stem Cell Biology CanBio 399 3 hrs/week; entire course 2002 Developmental Biology BioSci 20183 12 lectures (1 hr each) 2002 Stem Cells for Journalists One day session 2003 Developmental Biology BioSci 20183 13 lectures (1 hr each) 2003 Developmental Biology BioSci 20193 3 lectures (1 hr each) 2003 Special Topics in Immunology IMM 35500 2 lectures (1.5 hr each) 2003 Graduate Developmental Biology BioSci 21356 2 lectures (1.5 hr each) 2004 Developmental Biology BioSci 20183 13 lectures (1 hr each) 2004 Graduate Developmental Biology BioSci 21356 2 lectures (1.5 hr) 2005 Developmental Biology BioSci 20194 13 lectures (1hr each) 2005 Graduate Developmental Biology BioSci 21356 2 lectures (1.5 hr) 2005 Stem Cells and Medicine Medc 63300-01 1 lecture (2 hr) 2006 Developmental Biology BioSci 20194 13 lectures 2007 Stem Cells and Medicine Medc 63300-01 1 lecture (2 hr) 2008 Stem Cells and Medicine * Medc 63300-01 1 lecture (2 hr) Northwestern University Date Title of Course Number Contact Hours 2007 Molecular Mechanisms of Carcinogenesis IGP-480 2 lectures (2 hr) 2007 MSTP M2 journal club MSTP-401 1 session (90 min) 2008 Molecular Mechanisms of Carcinogenesis 2 lectures (2 hr) 2008 MSTP M2 journal club MSTP-401 1 session (90 min) 2009 Molecular Mechanisms of Carcinogenesis 2 lectures (2 hr) 2009 MSTP M2 journal club MSTP-401 1 session (90 min) 2009 Scientific Basis of Medicine INTERDEP 2003 1 lecture (50 min) 2010 MSTP M2 journal club MSTP-401 2 session (90 min) 2010 Molecular Mechanisms of Carcinogenesis 2 lectures (2 hr) 2010 Scientific Basis of Medicine INTERDEP 2003 2 lectures (50 min) 2011 Molecular Mechanisms of Carcinogenesis 2 lectures (2 hr) 2011 Scientific Basis of Medicine INTERDEP 2003 2 lectures (50 min)Teaching in the Research SettingA. Current Pre-doctoral Students:Ben Goldenson (MSTP student; supported by a TL1 grant)B. Current Postdoctoral Fellows:Monika Stankiewicz, PhDQiang (Jeremy) Wen, MD, PhD (Research Assistant Professor)Laure Gilles, PhD (Supported by a fellowship from the Rally Foundation)Benjamin Thompson, MD, PhD (Supported by a fellow award form LLS). Former Postdoctoral fellows:Marianne Greene, MD. Currently a surgical pathologist in private practiceSandeep Gurbuxani, MBBS, PhD. Currently an Assistant Prof. of Pathology at Univ. ChicagoZan Huang, PhD. Currently a Professor at Wuhan University Ganesan Keerthivasan, MBBS, PhD. Currently a senior post-doc with Peng Ji at NUSebastien Malinge, PhD. Now a faculty member at the Institut Gustave Roussy, FranceC. Current (pending) MD Fellows: 1. NoneD. Former MD Fellows:Rukhmi Bhat, MD Children抯 Memorial HospitalIrum Khan, MD, Northwestern Memorial Hospital E. Former Predoctoral Students:Erica Smith, Biochemistry. Received PhD 12/02. Currently a Research Assistant Professor at Northwestern UniversityYanfei Xu, Developmental Biology. PhD received 12/05. Currently a postdoctoral fellow at Northwestern UniversityCindy Leung, Cancer Biology. PhD received 12/06. Currently a medical science liaison with Bristol Myers Squibb Andrew Muntean, MGCB Program. PhD received 12/06. Currently an Assistant Professor at University of Michigan Gina Mundschau (nee Kirsammer), MGCB Program. PhD received 9/07. Currently a post-doctoral fellow at Children抯 Memorial Research CenterTodd Yezefski, Cancer Biology. MS. Currently a medical resident Lou Dore, IGP. Currently a post-doctoral fellow at the University of ChicagoTim Chlon, IGP. Currently a post-doctoral fellow at Cincinnati Children抯 HospitalF. Thesis Committees (Northwestern University):Sam McBreyerJenny KerschnerXiaoqing LinJessica SchulteEliza VakanaKa Tat SiuSam JensenBehnam NabetIrene LeeSam JensenG. Former Thesis Committees (University of Chicago):John Joslin, Cancer Biology Mauricio Cortes, Biochemistry Tammy Williams, Genetics Diana Boloton, MGCBYing Peng, Genetics Laurie Weiss, Human Genetics Kerstin Wolfe, Cancer Biology Johnnie Byrd, Cancer Biology Mark Sasaki, Cancer Biology Shannon Byrd, Developmental Biology David Young, Cancer BiologyRichard Martin, MGCBSteven Droho, MGCB Alexandria Dirlam, Immunology Markus Boos, Immunology H. Thesis Committees (other institutions) 1. Relja Popovic, Loyola University 2. Terra Lasho, Mayo ClinicI. Rotation Students: Current: 1. Erin Lambers Former:Tony Cooper, ImmunologyNoreen Ahmed, MGCBJohn Joslin, Cancer Biology Hilary Knobloch, MGCBKatie Sawai, ImmunologyAlexis Demonbreun, Dev BioAndrea Roche, Dev BioAvery Posey, GeneticsManop Buranapramest, NU IGP studentLouis Dore, NU IGP studentTim Chlon, NU IGP studentJennifer Kirschner, NU IGP studentTeresa Schuessler, NU IGP studentAbbey McEwen, NU MSTP studentMeghan Bliss-Moreau, NU IGP studentNehal Gosalia, NU IGP studentBen Goldenson, MSTP studentHsiang-Chun (Jimmy) Chang, MSTP studentSonia Olikara, DGPJ. Master抯 in Biotechnology Students: Current None Former Niket BubnaK. Undergraduate Students: Current None Former Brett TomsonKris Garcia-MasonSarah JilaniVeronica GalvalisiImge Hulur (PCBio program)Habib Bilfaqi, (NU CURE Program) Alex RosinskiRebecca MaddrellDario VillamarDan MillerL. High School Students (Former)Areli Valencia, Jones College PrepKachiu Lee, Illinois Mathematics and Science Academy. Research Grants/ContractsActive:Mechanisms of Leukemogenesis in Down syndromePrincipal Investigator, John Crispino 2.4 CalNIH/NCI $225,0002R01 CA101774 7/01/03-5/31/17The goals of this project are to: 1) Determine the necessity and sufficiency of selected Hsa21 genes in human AMKL and the murine model of DS-AMKL, 2) Identify the signaling pathways that are activated in AMKL, such as NFAT which lies downstream of DYRK1A, and 3) Determine the contribution of trisomy 21 to B-ALL. Mechanisms of erythroblast enucleationPrincipal Investigator, John Crispino 0 CalNIH/NIDDK $90,000R56 DK074693-06 9/01/12-7/31/13This is a bridge grant from the NIDDK to support a revision for a renewal of 揜ole of Survivin in development of megakaryocytes and erythroid cells. The first submission scored a 20%. Differentiation Therapy for Acute Megakaryocytic LeukemiaPrincipal Investigator, John Crispino 1.2 Cal Agency: Leukemia and Lymphoma Society $180,000 Translational Research Grant 10/01/09-09/30/12 The aims of this grant are to develop small molecule inducers of megakaryocyte polyploidization as new therapies for megakaryocytic leukemia. Novel therapies for pre-B cell ALLPrincipal Investigators J. Crispino and D. Weinstock 0.60 CalAgency: LLS $180,000Type: Translational Research Award 10/1/12 - 09/30/15The goals of this proposal are to perform pre-clinical studies to support development of HSP90 and DYRK1A kinase inhibitors as novel therapies for pediatric B-ALL in children with Down syndrome. Note: this grant has been awarded and will begin October 2012. CRLF2, JAK2 and Trisomy 21 in Acute Lymphoblastic Leukemia Principal Investigator, John Crispino 0.12 Cal Agency: Waxman Foundation $60,000Research Grant 07/01/11-06/30/13 The aims of this grant are to study the contributions of trisomy 21 to the increased risk of ALL in children with Down syndrome. Biology and Targeted Therapy for DS-ALL Principal Investigator, John CrispinoAgency: Rally Foundation $40,000Research Grant 07/30/11-07/29/14 This is a grant to support the work of a post-doctoral fellow, Dr. Laure Gilles.Center for Transcriptional Network Dynamics and Evolution Principal Investigator, K. White; Crispino, PI project 5 0.6 Cal Agency: NIH $89,306Type: P50 GM081892-01A1 9/1/08-8/31/13Project 5 is focused on deciphering the complex regulatory networks that govern the lineage specific differentiation of hematopoietic cells. Dr. Crispino抯 project is aimed at uncovering mechanisms of differential development of red blood cells and megakaryocytes. The Robert H. Lurie Comprehensive Cancer Center (RHLCCC)PI, S. Rosen; Crispino, Associate Director of Education and Training 1.8 CalAgency: NIH/NCI $15,969 (Salary) Type: P30 CA060553 08/01/01-07/31/12 The goals of this Cancer Center Support Grant are to conduct and support cancer research and to integrate cancer-related research throughout the university; to coordinate and integrate cancer-related activities of the University including community outreach initiatives; to develop and conduct cancer education programs; to promote and participate in state-of-the-are care of cancer patients at the affiliated hospitals of the McGaw Medical Center of Northwestern University and; to develop and implement the initiatives in cancer prevention and control research. These goals are accomplished through the activities of the 10 establish programs and 13 shared resources.Physical Sciences Oncology Center: Coding, Decoding, Transfer, and Translation of Information in CancerPI, J. Widom; Crispino, co-PI projects 3 and 4 1.2 CalAgency: NIH/NCI 牋牋牋牋 牋牋牋牋 牋牋牋牋 $15,969 (Salary)Type: U54CA143869 09/30/09-08/31/14牋牋牋牋Project 3 seeks to uncover the connection between higher-order chromatin structure and gene regulation mechanisms relevant to cancer. Project 4 will experimentally define the epigenetic changes resulting from the action of (1) a mutant kinase JAK2V617F, a causative factor in myeloproliferative disease; (2) a defined set of oncogenes that transform normal human cells to cancer cells (T antigen, ras, shRNA PP2a, telomerase); and (3) the changes in state of the MLH1 promoter that accompany gene silencing associated with promoter methylation, and reactivation that is induced by 5-aza-2'-deoxycytidine and is associated with DNA demethylation. Pending:NoneTo be submitted:Revised R01 application for Mechanisms of erythroblast enucleation: Anticipated March 2013Revised R01 application for Aberrant Megakaryopoiesis in MPNs (initial submission scored 20%): Anticipated October 2012New R01 application titled 揇evelopment of Polyploid Inducers as Novel Therapeutics in response to PAR-12-060 揝olicitation of Validated Hits for the Discovery of in vivo Chemical Probes. Anticipated October 2012Completed (J. Crispino, PI unless otherwise noted):Role of Survivin in development of megakaryocytes and erythroid cellsPrincipal Investigator, John Crispino 1.92 CalNIH/NIDDK $200,900R01 DK074693 4/01/07-3/31/12The major goals of this project are determining the requirements for survivin in megakaryocyte and erythroid cell development by analysis of conditionally targeted mice; investigating the precise role for survivin in terminal differentiation of erythroid cells by RNA interference; and assaying the consequences of overexpression of survivin on hematopoietic cell development in transgenic mice. Identification of Altered Molecular Signatures of Down Syndrome Induced Pluripotent Stem Cells Principal Investigator, John Crispino 1.2 Cal Agency: NIH/NHLBI $429,752 1RC1HL100168-01 9/30/09-9/29/11The goals of this grant are 1) to generate and characterize trisomic and euploid iPSCs from individuals with and without Down syndrome, 2) to compare the expression of miRNAs and mRNAs in undifferentiated DS and wild-type iPSCs and hematopoietic progenitors, and 3) to characterize the epigenome of DS versus euploid iPSCs. Role of Survivin in Development of Megakaryocytes and Erythroid CellsPrincipal Investigator, John Crispino 0 Cal Agency: NIH/NIDDK (DK074693) $32,025Recovery Act Administrative Supplement 7/01/09-6/30/11The goal of this supplement is to define the factors that regulate differential expression of survivin in red blood cells and megakaryocytes. Novel Approaches to Targeting Megakaryocytic DisordersPrincipal Investigator, John Crispino 0.12 Cal Agency: Waxman Foundation $60,000Research Grant 07/01/08-06/30/11 The aims of this grant are to identify the pathways by which GATA1 regulates megakaryopoiesis and to develop new targeted therapies for megakaryocytic disorders including PMF and AMKL. NIH/NIDDK R01DK61464 (04/01/02-03/31/07), 揈PS/MTB: A Novel Hematopoietic Transcription Factor Total Direct Costs (approx): $1, 100,000NIH/NCI P01 CA40046 (3/01/03-2/28/08), 揈tiology of Treatment-Induced Secondary Leukemia: Molecular Analysis of the Recurring Abnormalities of Chromosome 5 in Malignant Myeloid Disorders Principal Investigator, Michelle Le Beau, Crispino Co-PI, Project 3. The Cancer Research Foundation, Young Investigator Award (01/01/01-12/31/01), "The Role of Lmo2 in T-cell Leukemia." Total Direct Costs $50,000The Louis Block Fund for Basic Research and Advanced Study (7/1/01-6/30/02), 揇o the Hematopoietic Regulators GATA-1 and FOG-1 Contribute to Human Leukemia? Total Direct Costs $25,000The American Cancer Society Institutional Research Grant (11/1/00-10/31/01), 揟he Role of Lmo2 in T-Cell Leukemia. Total Direct Costs $17,500Howard Hughes Medical Institute Pilot Award (1/1/00-12/31/01), 揟he Role of Lmo2 in T-Cell Leukemia. Total Direct Costs $40,000The Aplastic Anemia and MDS International Foundation, Post-doctoral award (for Dr. Marianne Greene) (07/01/01-06/30/03), "Knockout of the GATA-1:FOG-1 Interaction: Implications for Myelodysplasia." Total Direct Costs: $60,000 The V Foundation for Cancer Research, V Scholar Award (08/01/01-07/31/03), "Characterization of Angiogenic Transcription Factors." Total Direct Costs $100,000Burroughs Wellcome Fund Career Award in the Biological Sciences (09/01/00-08/31/03), "Functional Characterization of Hematopoietic Transcription Factors Complexes." Total Direct Costs $386,000American Society of Hematology Junior Faculty Award (7/01/02-6/30-04). 揜ole of EPS, A Novel SCL-interacting Protein, in Hematopoiesis. Total Direct Costs $120,000 The Elsa Pardee Foundation, Research Grant (1/01/04-12/31/04), 揇eciphering the Role of Chromosome 21 in Leukemogenesis. Total Direct Costs $180,000Chicago Biomedical Consortium Catalyst Award (01/01/08-12/31/08), Gene Regulatory Networks Directing Hematopoietic Cellular Fates. Total Direct Costs $199,538March of Dimes, Research Award (6/01/07-5/31/10), 揟he Roles of ETS2 and ERG in the Neonatal Leukemia Associated with Down syndrome. Total Direct Costs $270,000Leukemia and Lymphoma Society (07/01/05-6/30/10), 揋ATA-1 mutations in the megakaryoblastic leukemia of Down syndrome. Total Direct Costs: $525,000Presentations (past 5 years and future invitations)2007 Gordon Conference, Cell Biology of Megakaryocytes and Platelets, Ventura, CA. Session Chair.Gordon Conference, Red Cells, Aussois, France. Invited speaker. (Unable to attend; graduate student Cindy Leung presented in my place).Seventh International Workshop on Myeloid Stem Cell Development and Leukemia, Annapolis, MD, Invited speaker. Yale University Center of Excellence in Hematology Seminar Series. Invited speaker. University of Illinois at Chicago, Hematology/Oncology Research Grand Rounds. Invited speaker. 2007 Myeloid Workshop (affiliated with the ASH meeting), Invited presentation.2008 University of Pennsylvania Hematology/Oncology Seminar Series. Invited speaker. Modern Trends in Human Leukemia, XVII Wilsede Meeting, Wilsede, Germany. Invited speaker. Oxford University, UK, John Radcliffe Hospital Divisional Seminar, Invited Speaker.Biomedicum Helsinki Research Center, Helsinki, Finland. Biomedicum Seminar Series Center for Blood Research, Blood Center of Wisconsin, Invited speaker2009 FASEB Conference on Hematologic Malignancies, Saxton Rivers, VT, Invited Speaker. Gordon Conference, Cell Biology of Megakaryocytes and Platelets, Galveston, TX, Invited Speaker.Gordon Conference, Red Cells, Biddeford, Maine, Invited Speaker.Indiana University, Wells Center for Pediatric Research, Invited speakerUniversity of Kansas, Invited speaker in Cancer & Developmental Biology Research Seminar Series University of Texas Southwestern, Cell Biology Department Seminar Series, Invited speaker. Eighth International Workshop on Myeloid Leukemia, Annapolis MD Invited speaker (unable to attend). International Conference in Differentiation Therapy, Chicago, IL Invited speaker. Memorial Sloan Kettering Cancer Center, NY, Levine lab meeting, Invited speaker. 2009 Myeloid Workshop (affiliated with the ASH meeting), Invited presentation.2010 5Th Annual Houston Conference on Myelodysplastic Syndromes and Myeloproliferative Neoplasms, invited speaker. Blood Dyscrasias and Transfusion Medicine Symposium to Honor Dick Aster, Blood Center of Wisconsin, Milwaukee Wisconsin, invited speaker.5th Post-ASH Workshop on CML and MPN, invited speaker. Children抯 Hospital of Michigan, Grand Rounds, invited speaker. University of Chicago Cancer and Developmental Biology Seminar Series, invited speaker.Loyola University Stitch School of Medicine Molecular Biology Seminar Series, invited speaker. 5th Annual GATA Factor Meeting, Sendai, Japan, invited speaker. 17th Hemoglobin Switching Conference, Oxford, UK, invited speaker. University of Michigan, Department of Pathology, invited speaker. Children抯 Hospital of Philadelphia, Heme/Onc Seminar Series, invited speaker. 2011 Organizer, FASEB Conference on Hematologic Malignancies, Saxton Rivers, VTInvited to participate as Speaker and Discussion Leader, 4th Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets. Galveston, TX. Invited to speak at the 2011 Gordon Conference on Red Cells, Andover, New Hampshire. Buck Institute of Aging, San Francisco, CA, invited speaker.1St International Meeting on MPNs, Florence Italy, invited speaker. 6Th Annual Houston Conference on Myelodysplastic Syndromes and Myeloproliferative Neoplasms, invited speaker.Invited to speak in the European Hematology Meeting: AML 揗olecular? Mandelieu, France.Invited to speak 揗aking Blood from Progenitors Ex-vivo Workshop, Rome, Italy.Invited to speak at the Linda Crnic Institute for Down syndrome at the University of Colorado. 2011 Myeloid Workshop (affiliated with the ASH meeting), Invited presentation.2012 Invited to speak in the Buck Institute Symposium 揝tem Cell Research and AgingInvited to participate as Keynote Speaker, Midwest Blood Club Annual Symposium Invited to speak at Massachusetts General Hospital Cancer Center.Invited to speak at the University of Nebraska Medical Center.Invited to present grand rounds at the Sheba Medical Center, Tel Hashomer, Tel Aviv, IsraelInvited to speak in the 18th annual Hemoglobin Switching Conference, Monterey CA.Invited to speak at the European Hematology Association 2012 Congress, AmsterdamInvited to speak in the MD Anderson 8th International Hematologic Malignancies 2012 Conference, Houston, TXInvited to speak in the Cold Spring Harbor Asia/13th International Conference on Differentiation Therapy, Suzhou, China. Invited to speak in the Ninth Annual Myeloid Meeting, Cincinnati, OH Invited participant of the 2nd Annual Myeloproliferative Neoplasms Meeting, Florence, Italy2013 Invited to speak in the FASEB Conference on Hematologic MalignanciesInvited to speak in the Gordon Research Conference 揅ell biology of Megakaryocytes and Platelets. Invited to speak and co-organize the 揟hird Florence MPN meeting? Florence, Italy.Scholarly BibliographyA: Original peer reviewed articlesLessard, PA, Allen, RD, Bernier, F, Crispino, JD, Fujiwara, T, and Beachy, RN. (1991). Multiple nuclear factors interact with upstream sequences of differentially regulated b?conglycinin genes. Plant Mol. Biol. 16:397-413. Crispino, JD, Blencowe, BJ, and Sharp, PA. (1994). Complementation by SR proteins of pre-mRNA splicing reactions depleted of U1 snRNP. Science 265:1866-1869.Crispino, JD and Sharp, PA. (1995). A U6 snRNA:pre-mRNA interaction can be rate limiting for U1-independent splicing. Genes & Development 9:2314-2323.Crispino, JD, Mermoud, JE, Lamond, AI, and Sharp, PA. (1996). Cis-acting elements distinct from the 5 splice site promote U1-independent pre-mRNA splicing. RNA 2:664-673.MacMillan, AM, McCaw, PS, Crispino, JD, and Sharp, PA. (1997). SC35 mediated reconstitution of splicing in U2AF-depleted nuclear extracts. Proc. Natl. Acad. Sci. 94:133-136.Crispino, JD, Lodish, MB, MacKay, JP and Orkin, SH. (1999). Use of altered specificity mutants to probe a specific protein-protein interaction in differentiation: the GATA-1:FOG complex. Molecular Cell 3:219-228.Deconinck, AE, Mead, PE, Tevosian, SG, Crispino, JD, Katz, SG, Zon, LI, and Orkin, SH. (2000). FOG acts as repressor of red blood cell development in Xenopus. Development 127:2031-2040.Nichols, KE*, Crispino, JD*, Poncz, M, White, JG, Orkin, SH, Maris, JM and Weiss, MJ. (2000). Familial dyserythropoietic anemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Gen. 24: 266-270.* These authors contributed equally to this work.Querfurth, E, Schuster, M, Kulessa, H, Crispino, JD, Doderlein, G, Orkin, SH, Graf, T and Nerlov, C. (2000). Antagonism between C/EBPb and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes and Development 14:2515-2525.Crispino, JD, Lodish, MB, Thurberg, BL, Litovsky, SH, Collins, T, Molkentin, JD and Orkin, SH. (2001). Proper coronary vasculature development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. Genes and Development 15:839-844.Wechsler, J, Greene, M, McDevitt, MA, Anastasi, J, Karp, JE, LeBeau, MM, and Crispino, JD. (2002). Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics 32:148-152.Chang, AN, Cantor, AB, Fujiwara, Y, Lodish, M, Droho, S, Crispino, JD, and Orkin SH. (2002). GATA factor dependence of the multitype zinc finger protein FOG-1 for its essential role in megakaryopoiesis. Proc. Natl. Acad. Sci. 99:9237-9242. Tevosian, SG, Albrecht, KH, Crispino, JD, Fujiwara, Y, Eicher, EM, and Orkin, SH. (2002). Gonadal differentiation, sex determination, and normal Sry expression in mice requires direct interaction between transcription partners GATA4 and FOG2. Development 129: 4627-4634. Wang, X, Crispino, JD, Letting, DL, Nakazawa, M, Poncz, M, and Blobel, GA. (2002). Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J. 21:5225-5234.Karnauskas, R, Niu, Q, Talapatra, S, Plas, D, Greene, ME, Crispino, JD, and Rudin, C. (2003). Bcl-xl and Akt cooperate to promote leukemogenesis in vivo. Oncogene 22: 688-698.Mundschau, G, Gurbuxani, S, Gamis, AS, Greene, ME, Arceci, RJ, and Crispino, JD. (2003). Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 101:4298-4300. Smith, ED, Xu, Y, Tomson, BN, Leung, CG, Fujiwara, Y, Orkin, SH, and Crispino, JD. (2004). More than blood, a novel gene required for mammalian post-implantation development. Mol. Cell Bio 24:1168-1173. Muntean, A. and Crispino, JD. (2005) Differential requirements for the activation and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 106:1223-1231.Gurbuxani, S, Xu, Y, Keerthivasan, G, Wickrema, A, and Crispino, JD. (2005) Differential requirements for Survivin in hematopoietic cell development. PNAS 102: 11480-11485 (track II submission).Xu, Y, Leung, CG, Lee, DC, Kennedy, BK, and Crispino, JD. (2006) MTB, the murine homologue of condensin II subunit CAP-G2, represses transcription and promotes erythroid cell differentiation. Leukemia 20:1261-1269. Walters, DK, Mercher, T, Gu, TL, O扝are, T, Tyner, JW, Loriaux, M, Goss, VL, Lee, KA, Eide, CA, Wong, MJ, Stoffregen, EP, McGreevey, L, Nardone, J, Moore, SA, Crispino, J, Boggon, TJ, Heinrich, MC, Deininger, MW, Polakiewicz, RD, Gilliland, DG, and Druker, BJ. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10:65-75.Muntean, AG, Pang, L, Poncz M, Dowdy, SF, Blobel, GA, and Crispino, JD. (2007) Cyclin D/Cdk4 is regulated by GATA-1 and is required for megakaryocyte growth and polyploidization. Blood 109:5199-5207. Joslin, JM, Fernald, AA, Tennant, TR, Davis, EM, Kogan, SC, Anastasi, J, Crispino, JD and Le Beau, MM. (2007). Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development myeloid disorders. Blood 110:719-726.Leung, CG, Xu, Y, Mularski, B, Liu, H, Gurbuxani, S, and Crispino, JD. (2007). Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. Journal of Experimental Medicine 204:1603-1611.Huang, Z, Richmond, TD, Muntean, A, Barber, DL, Weiss, MJ, and Crispino, JD. (2007) STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. Journal of Clinical Investigation 117:3890-3899.Kirsammer, G, Jilani, S, Liu, H, Davis, E, Gurbuxani, S, Le Beau, MM, and Crispino, JD. (2008) Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood, 111:767-775. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/18174176?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"Kang JA, Zhou Y, Weis TL, Liu H, Ulaszek J, Satgurunathan N, Zhou L, van Besien K, Crispino J, Verma A, Low PS, Wickrema A. (2008) Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. Journal of Biological Chemistry 283:6997-7006.McCrann, DJ, Yezefski T, Nguyen HG, Papadantonakis, N, Liu H, Wen Q, Crispino JD, and Ravid K. (2008) Survivin overexpression in transgenic mice alone does not alter megakaryocyte ploidy nor interfere with erythroid/megakaryocytic lineage development. Blood 101:4092-4095. Stankiewicz, MJ, and Crispino JD. (2009) ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 113:3337-3347. Wen, Q, Leung, C, Huang, Z, Small, S, Reddi, AL, Licht, JD and Crispino JD. (2009) Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood 114: 153-156.Abdel-Wahab, O, Mullally, A, Hedvat, C, Garcia-Manero, G, Patel, J, Wadleigh, M, Malinge S, Yao, J, Kilipavaara, O, Bhat, R, Huberman, K, Thomas, S, Dolgalev, I, Heguy, A, Paietta, E, Le Beau, M, Beran, M, Tallman, MS, Ebert, BL, Kantarjian, HM, Stone, RM, Gilliland, DG, Crispino, JD, and Levine, RL. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147.Chou, ST, Khandros, E, Bailey, C, Nichols, KE, Vakoc, CR, Yao, Y, Huang, Z, Crispino, JD, Hardison, RC, Blobel, GA, and Weiss, MJ. (2009) Graded repression of PU1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood 114:983-994.Huang, Z, Dore, LC, Li, Z, Orkin, SH, Feng, G, Lin, S, and Crispino JD. (2009) GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Bio. 29:5168-5180.Gao Z, Huang, Z, Olivey, HE, Gurbuxani, S, Crispino, JD, Svensson, E. (2010) FOG-1 mediated recruitment of NuRD is required for cell lineage re-enforcement during hematopoiesis. EMBO J., 29:457-468.Keerthivasan G, Small, S, Liu, H, Wickrema A, and Crispino, JD. (2010) Vesicle Trafficking plays a novel role in erythroblast enucleation. Blood 116:3331-3340. Article featured on Blood Cover and by an accompanying Inside Blood editorial.Huang, QQ, Perlman, H, Huang, Z, Birkett, R, Kan L, Agrawal, H, Misharin, A, Gurbuxani, S, Crispino, JD, and Pope, RM. (2010) FLIP: a novel regulator of macrophage differentiation and granulocyte homeostasis. Blood 116:4968-4977.Small, S, Keerthivasan, G, Huang, Z, Gurbuxani, S, and Crispino, JD. (2010) Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia 24:1920-1926. Eliades A, Papadantonakis N, Bhupatiraju A, Burridge KA, Johnston-Cox HA, Migliaccio AR, Crispino JD, Lucero HA, Trackman PC, Ravid K. (2011) Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem 286: 27630-8. Park, E, Gang EJ, Hsieh, YT, Schaefer, P, Chae, S, Klemm, L, Huantes, S, Loh, M, Conway, EM, Kang, ES, Koo, HH, Hoffman WK, Heisterkamp, N, Pelus, L, Keertivasan, G, Crispino, J, Kahn, M, M黶chen, M, Kim, YM. (2011) Targeting Survivin Overcomes Drug Resistance in Acute Lymphoblastic Leukemia. Blood 118:2191-2199.Mali, RS, Ramdas, B, Ma, P, Munugalavadla, V, Sims, E, Shi, J, Wei, L, Lewis, T, Stern, AM, Wen, Q, Crispino, JD, Boswell, S, and Kapur, R. (2011) Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20:357-369. Rice, KL, Lin, X, Wolniak, K, Ebert, BL, Berkofsky-Fessler, W, Buzzai, M, Sun, Y, Xi, C, Elkin, P, Levine, R, Golub, T, Gilliland, DG, Crispino, JD, Licht, JD, and Zhang, W. (2011) Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal 1, e40; doi:10.1038/bcj.2011.39.Galat V, Malchenko S, Galat Y, Ishkin, A, Nikolsky, Y, Kosak, ST, Soares MB, Iannaccone, P, Crispino, J, Hendrix, MJC. (2012) A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes upon transition to squamous epithelium. Stem Cells and Development 21:1250-1263.Malinge, S, Bliss-Moreau M, Kirsammer, G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. (2012) Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J. Clin. Invest. 122:948-962.Dor? LC, Chlon, TM, Brown, CD, White, KP, and Crispino, JD. (2012) Chromatin occupancy analysis reveals genome wide GATA factor switching during hematopoiesis. Blood 119:3224-3733. Wen, Q, Goldenson, B, Silver, SJ, Schenone, M, Huang, Z, An, W.F, Lewis, T, Dancik, V, Thiollier, C, Wang, L-Z, Diebold, L, Bliss-Moreau, M, VerPlank, L, Moore, CB, Vokes, MS, Scherer, C, Carpenter, AE, Tolliday, N, Clemons, P, Mishra, R, Vemula, S, Shi, J, Wei, L, Kapur, K, Lopez, C, Gerby, B, Bellerini, P, Pflumio, F, Gilliland, DG, Goldberg, L, Birger, Y, Izraeli, S, Gamis, AS, Smith, FO, Woods, WG, Goh, B-C, Root, DE, Carr, SA, Gould, R, Mercher, T, Bradner, J, Schreiber, S, Stern, AM, Crispino, JD. Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. Cell 150:575-589. Chlon, TM, Dor? LC, and Crispino, JD. Cofactor-mediated restriction of GATA-1 chromatin occupancy coordinates lineage-specific gene expression. Molecular Cell 119(16):3724-33.Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Gu間an J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J. Exp. Med Pre-published on line October 8, 2012.Keerthivasan G, Liu, H, Gump JM, Dowdy SF, Wickrema A, and Crispino JD. (2012) A novel role for survivin in erythroblast enucleation. Haematologica. Pre-published on line April 4, 2012.Khan, I, Huang Z, Wen Q, Stankiewicz MJ, Diebold L, Gurbuxani S, Finke CM, Laslo TL, Koppikar P, Pardanani A, Levine RL, Stein B, Altman J, Tefferi, A, and Crispino JD. AKT is a therapeutic target in myeloproliferative neoplasms. In revision, Blood. Malinge S, Thiollier C, Chlon TM, Dor LC, Diebold L, Bluteau O, Mabialah V, Vainchenker W, Dessen P, Winandy S, Mercher T and Crispino JD. Regulation of megakaryopoiesis through functional antagonism between Ikaros and GATA-1. Submitted. Malchenki S, Fatima Boaldo MF, Galat V, Vanin EF, Seftor REB, Crispino, J, Hendrix MJC, and Soares, MB. OTX2 is distinctively expressed at the onset of hESC neuronal differentiation. Submitted.B: Editorials/Reviews/Chapters/Books/CommentariesPeer-reviewed reviews:Gurbuxani, S, Vyas, P. and Crispino, JD. (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome, Blood 103:399-406. Malinge, S, Izraeli, S, and Crispino JD. (2009) Insights into the manifestations, outcomes and mechanisms of leukemogenesis in Down syndrome. Blood 113:2619-2628. Dore, LC and Crispino, JD. (2011) Transcription factor networks in erythroid and megakaryocyte development. Blood 118:231-239.Stein, B, Crispino, JD, Moliterno, A. (2011) Janus Kinase-Inhibitors: An Update on the Progress and Promise of Targeted Therapy in the Myeloproliferative Neoplasms. Current Opinion in Oncology 23:609-616. Keerthivasan, G, Wickrema, A, and Crispino, JD. (2011) Erythroblast enucleation. Stem Cells International 2011:139851. Epub 2011 Oct 5. Wen, Q, Goldenson, B, and Crispino, JD. (2011) Normal and Malignant Megakaryopoiesis. Expert Reviews in Molecular Medicine 2011 Oct 21;13:e32.Khan, I, Malinge, S, and Crispino, JD. Myeloid leukemia in Down syndrome. (2011) Critical Reviews in Oncogenesis 16:25-36.Chlon, T and Crispino JD. Combinatorial regulation of tissue specification by GATA and FOG factors. Development 139:3905-16. Invited Reviews/Commentaries (not peer reviewed):Crispino, JD. (2005) GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatric Blood and Cancer 44:40-44.Crispino, JD. (2005) GATA-1 in normal and malignant hematopoiesis, Seminars in Cell and Developmental Biology 16:137-147.Crispino, JD. (2006) Up and Down in Down syndrome: AMKL. Blood 107:1251-1252. (Inside Blood invited commentary)Mundschau, G and Crispino, JD. (2006) GATA1s goes germline. Nature Genetics 38:741-742. Muntean, AG, Ge, Y, Taub, JW, and Crispino, JD. (2006) Transcription Factor GATA-1 and Down syndrome Leukemogenesis. Leukemia and Lymphoma 47: 986-997.Vyas, P, and Crispino, JD. (2007) Molecular Insights into Down syndrome associated leukemia. Curr. Op Pediatrics 19:9-14.Crispino, JD. (2007) On the Origins of Megakaryocytes. Blood 109: 1340-1341. (Inside Blood invited commentary) Wickrema, A and Crispino, JD. (2007) Erythroid and Megakaryocytic Transformation. Oncogene, 26:6803-6815.Malinge, S and Crispino, J. (2010) Notch: of mice and men? Inside Blood invited commentary. Blood 116: 5438-5439.Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. (2012) HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/22460584"Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium. Am J Hematol. 87:562-568.Crispino, JD.(2012) JAKing up AML1-ETO. Inside Blood invited commentary. Blood 120: 703-704. Book chapters:Tsang, AP, Crispino, JD and Orkin SH. (2000) The role of GATA-1 and FOG in erythroid and megakaryocyte differentiation. In Transcription Factors: Normal and Malignant Development of Blood Cells. K. Ravid and J. Licht. eds. (Wiley-Liss, New York). pp. 1-12.Lee, C-J, Huang, Z, Jiang, H, Crispino, J, and Lin, S. (2009) Cancer biomarker priorization: assessing the in vivo impact of in vitro models by in silico mining of microarray database, literature, and gene annotation. In Biological Data Mining. JY Chen and S. Lonardi, eds. (CRC Press, New York) pp 615-627.C: Case reports, technical notes, and letters:Letters to the editor:Taub, JW, Mundschau, G, Ge, Y, Poulik, JM, Qureshi, F, Jensen, T, James, SJ, Matherly, LH, Wechsler, J, and Crispino, JD. (2004) Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104:1588-1589.Norton, A, Fisher, C, Liu, H, Wen, Q, Mundschau, G, Fuster, JL, Hasle, H, Zeller, B, Webb, D, O扢arcaigh, A, Sorrell, A, Hilden, J, Gamis, A, Crispino, JD and Vyas, P. (2007). Analysis of JAK3, JAK2, and c-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 110:1077-1079.Bhat, R, Malinge, S, Gamis, AS, Sorrell, AD, Hilden, JM, Ketterling, RP, Paietta, E, Tallman, MS, and Crispino, JD. (2009) Mutational analysis of candidate tumor associated genes in acute megakaryocytic leukemia. Leukemia 23:2159-2160.D: Proceedings and non-refereed papersCrispino, JD and Orkin, SH. (2002). The use of altered specificity mutants to probe specific protein-protein interactions involved in the activation of GATA-1 target genes. Methods 26:84-92. Greene, ME, Mundschau, G, Wechsler, J, McDevitt, M, Gamis, A, Karp, J, Gurbuxani, S, Arceci, R, and Crispino, JD. (2003). Mutations in GATA1 in both Transient Myeloproliferative Disorder and Acute Megakaryoblastic Leukemia of Down syndrome. Blood Cells, Molecules and Diseases, 31:351-356. F: PatentsCrispino, JD',-.>      ( U t   + TU\]^qu/礴礅傺叛撑ε奄褲奄捬捹褔褔質褆囇傺囐奄奄裶h芢Bh馷OJQJhpHh馷OJQJhh馷OJQJh聾6h馷OJQJh馷6丱JQJh｜h馷0JOJQJ#jh｜h馷OJQJUjh馷OJQJUh馷OJQJh馷5丱JQJ h馷5 h馷CJh聾6h馷CJh馷 h馷;,-./V) S €   ) u 0p刾^刾 ?h0p@ 0p@& `p p @& p ?hp @ 0 [   + r @"|?h0p@刾剱鱚刾`剱鱣d馷?h0p@劆刞鷁劆`刞鷊d馷 刾匄鴁刾`匄鴊d馷h0p@gd馷 h0p刾剱鰼&^刾`剱鱣d馷 0p@& h0pgd馷 0p刾^刾gd馷O/;|&Ly蟒Lhp 剺刪]剺刪gd馷蟒Lhp 剺剺d馷h0p@&gd馷 0p@&?h0p@刾剱鱚刾`剱鱣d馷!8b$[S4th0p@&gd馷蟒Lhp 剺剺d馷蟒Lhp 剺刪]剺刪gd馷>o3Si J=蟒Lhp 剺劆刞鷀剺劆`刞蟒Lhp剺勜 ?鯹剺勜 `?蟒Lhp 剺剺 0p@&蟒Lhp 剺刪]剺刪gd馷3 \"????????&???,?@-L-?????? . .-.澍噘噶澿鴳帏嗻嗻嗻~s~shhk0lh馷OJQJh3Jh馷5??*h馷5??*h"`h馷OJQJh3Jh馷5丱JQJh3Jh馷5?*h3Jh馷>*h馷>*OJQJh馷6丱JQJh"Q-h馷6丱JQJhk0lh馷6丱JQJ h糿fh馷h馷h馷5丱JQJh芢Bh馷OJQJh馷OJQJ(=yUAod&蟒Lhp 剺兀&]剺d馷蟒Lhp 剺兀&]剺蟒Lhp 剺刾剱鱙剺刾`剱鱣d馷蟒Lhp 剺剺 V{ F x !b!???蟒Lhp 剺刪]剺刪gd馷蟒Lhp 剺剺蟒Lhp 剺刾]剺刾蟒Lhp 剺刪]剺刪蟒Lhp 剺兀&]剺?!"??V$??3%???pkgd馷蟒Lhp 剺兀&]剺蟒Lhp 剺剺蟒Lp 剺刪凗剺刪`凗d馷蟒Lp 剺刪凗剺刪`凗蟒Lhp 剺剺d馷蟒Lhp 剺兀&]剺d馷蟒Lhp 剺刾]剺刾 ??&l&??Z'??N(??,)x)?*Q*蟒Lh 剺剺蟒Lh X 剺剺蟒Lh€ X 剺剺蟒Lh X 剺剺 蟒Lhp 剺剺P X (#Q*????)+c+??,Y,??-a-??? ...蟒Lhp 剺剺P X (#纆d馷蟒Lh 剺剺蟒Lh 剺剺d馷..e.f.???#/g/h/??-0h0? 11 & F蟒Lp 剺剺d馷 & F蟒Lp 剺剺蟒Lp 剺剺 & F蟒Lp 剺剺蟒Lhp 剺剺蟒Lp 剺剺d馷 & F蟒Lp 剺剺d馷-.e.f.?g/? 1 11/1216171O1|1??????+5???}7??888+8<:=:>:n:v:€:孃苞氟龙;,;/;=;>;K;L;\;];k;v;w;x;欫篼<<澍澍嬴漤澍眸澍硒澍娩夸澍眸澍澍澍澍带带带带澍爺h獺oh馷5丱JQJh馷5丱JQJhE]h馷OJQJhXh馷OJQJh馷hHh馷OJQJhHh馷OJQJh"h馷OJQJh馷6丱JQJh獺oh馷OJQJh馷OJQJ:1.17181O1|1???@2?!3?4Y4????+5蟒Lp 剺刪]剺刪gd馷 & F 蟒Lp 剺剺d馷 & F 蟒Lhp 剺剺d馷蟒Lhp 剺剺+585H5U5e5r5}5???????676K6a66?? & F蟒Lp 剺剺蟒Lhp 剺剺蟒Lhp 剺剺d馷 & F蟒Lhp 剺剺d馷??6707D7c7|7}7????8 88!8+8C8V8s8? & F 蟒Lp 剺剺h蟒Lhp 剺剺蟒Lp 剺剺 & F蟒Lp 剺剺????? 9'9A9d9????:*:=:>:f:o:u:w:蟒Lhp 剺剺d馷蟒Lhp 剺剺 & F 蟒Lhp 剺剺d馷 & F 蟒Lp 剺剺w:€:孃岤?柄氟跟龙晰帔睑;;>;L;];l;w; & F蟒L 剺?]剺?gd馷蟒Lhp 剺剺 & F蟒Lp 剺剺d馷蟒Lhp 剺剺d馷w;x;欫见篼酐觖<<<G<z<掽更勻]勻gd馷gd馷$ ] a$gd馷蟒Lhp 剺剺d馷蟒Lhp 剺兀&]剺 & F蟒L 剺]剺gd馷蟒Lp 剺剺<<<<G<邳颀觚>撖$?J?K??碄礍谸顯 AAAA A$A;AXA^ApAqA6BvBwB~B傿払睟矪蹯囔赝亓囟囟熵貚~崀崀崀崀崀s靚fnf^hmO@h馷5hh馷5 h馷5h鵙 h馷OJQJh1h馷OJQJ^JaJh馷OJQJ^JaJh1h馷5丱JQJ^JaJh馷5丱JQJ^JaJh騤h馷OJQJh譟Th馷5丱JQJh艬h馷OJQJh馷OJQJh獺oh馷5丱JQJh馷5丱JQJh馷5?*OJQJ$更觚>P>j>慆K?L????%@碄礍谸A5AqA6B$a$gd馷 劼凗 ^劼`凗d馷$ 劼凗 ^劼`凗$gd馷gd馷#披p @ \€lX ?gd馷6BvBwB矪鐱C:C糃紺鏑D5D_D癉盌頓8E]E廍橣欶覨 勑]勑gd馷#披p @ \€lX ?gd馷1$H$gd馷gd馷勻]勻gd馷矪糃紺鏑C4D5D_DzD嘍淒滵瓺疍癉頓橣欶覨(G/G8GGGHGIGJGPG]GeGfGJJ9J;J€J肑螶鮆鯦鳭JKK1K籑糓阖秫锾沉狓柳摿飮飮鴟鴟hh馷OJQJhwmh馷5丱JQJh訲h馷@堼OJQJ$h訲h馷5丂堼B*OJQJphh訲h馷5丂堼OJQJh訲h馷OJQJh訲h馷5丱JQJhmO@h馷OJQJhmO@h馷5丱JQJh馷5丱JQJh馷OJQJ-覨 GJGxGJJ€J籎J2K籑糓臡蔒薓躆7N8N癗盢嘜圤塐絆gd馷1$H$gd馷刏H$]刏gd馷 勑]勑gd馷 H$gd馷糓腗臡蔒薓躆鳰N N,N6N7N圤塐扥絆綩PRiR-TsT漊訳奮抆竈蒦蝆_+_,_-_瞋蟔衉E`F`G`f`渀`cc0d蜴塾庞拱塾褂坝坝坝坝坝嬘嬘嬘嬘€影u觰影影影h| h馷OJQJhb7Gh馷OJQJhBh馷OJQJh馷5?*OJQJh| h馷OJQJ^JaJh馷5丱JQJh譟Th馷5丱JQJh?h馷5?*OJQJh馷OJQJh?h馷OJQJh8h馷>*OJQJh8h馷5?*OJQJ-絆綩P8PSPwPRRiR漅繰鏡,T-TsT蠺#披p @ \€lX ?gd馷gd馷 刪]刪gd馷 劼凗 ^劼`凗d馷$ 劼凗 ^劼`凗$gd馷$a$gd馷$a$蠺 U淯漊訳 V1V[VWW焀燱5Y6Y餣馳乑俍[[? $ ] a$d]$ 劼凗 ^劼`凗$  ] $a$gd馷[鏪鑋圽塡J]K]騗骫塣奮,_-_蟔衉e`f`g`沗渀`嘺勑^勑gd馷 勑?齘勑`?齡d馷gd馷  d] gd馷$a$ $刪]刪a$?嘺坅譨鵤鸻QbRb眀砨ccc[c\c穋竎 dd`dad╠ヾ猟eedeee勑^勑gd馷勑`勑gd馷gd馷0dEd╠猟fSfhhiiKjMj巎恓iknkwkxkyk鬹鰇阬靗0m2m鋗鮩 n/n減瀙LqNq苢萹srur媠蹴漤仨添理错错╉╀頋響硖韱韱礓韟韟韟韓hrh馷H*OJQJh圞h馷H*OJQJh?h馷OJQJh LQh馷H*OJQJh蜧uh馷H*OJQJh揧_h馷OJQJhh馷H*OJQJh唚0h馷H*OJQJh揧_h馷H*OJQJh馷B*OJQJphh馷5丱JQJh馷OJQJhEmuh馷OJQJ'餰馿RfSf癴眆ggkglg縢纆hhh噃坔i 勑?齘勑`?齡d馷勑^勑gd馷 勑勑^勑`勑gd馷#? 0` P€@勑1$7$8$H$^勑gd馷勑`勑gd馷gd馷iiLiMi巌廼鑙閕IjJj媕宩衘裫kkgkhkik筴簁SlTl猯玪鑜閘 勑?齘勑`?齡d馷勑^勑gd馷gd馷閘.m/m漨瀖鱩鴐HnIn╪﹏鵱鷑鹡PoQo鋙錹$p%p乸俻詐誴&q'q勑`勑gd馷gd馷勑^勑gd馷'q搎攓rrUrVr硆磖祌ssdses箂簊裺襰鮯鰏瞮磚刪^刪gd馷 & Fgd馷蟒Lp 刪^刪gd馷蟒Lp @&gd馷 ?gd馷gd馷勑^勑gd馷媠箂裺襰誷鮯4tLtJuLuvu杣榰渦磚蘵bvjvkvnv{v噕髒wwww!w硍秝竪輜閣Nxdxgxrx~x.yypy|y鑩髖魕鱵zz簔縵羫蘻蛕蟴衵3{?{||獆詜謡趞魘 }U~k~m~舿褈駘蹴漤偎礓砻砗礓礓砗礓礓砗礓礓砗漤漤轰礓砗礓礓砗礓礓砗砗礓喉漤庙喉漤漤轰礓h馷6丱JQJh馷OJQJh竈h馷5?*OJQJh馷5?*OJQJh馷5丱JQJh馷OJQJh\h馷OJQJI磚zv{vww聎脀qxrxHyIyzz { {騶魘w~x~FG:€;€KL 袀gd馷刪^刪gd馷 & Fgd馷駘鰚*9:<€+€-€W€c€.9:=Ua Zf簜聜脗艂!9?w|}€崈觾醿閮鷥=JKMYZkw R`眳秴箙 焼▎獑穯竼W鲱鲱孱孱鲥铄铞铄铄铞铄铄铞铄铄铞铞铄钯速劫劫速差孱鲥铄铞孱孱鲱孱h馷CJOJQJhSJh馷OJQJh馷6丅*OJQJphh馷5丅*OJQJphh馷B*OJQJphh馷5丱JQJh馷OJQJh馷6丱JQJB袀褌崈巸Z[迏邊穯竼鐖鑸訅詨賷趭瀷煁kl凕`凕gd馷$ 劼凗 ^劼`凗$gd馷gd馷 & Fgd馷刪^刪gd馷WbTb蠄請貓1>缐艍蕣貖賷&m帇閶鰦V[lm鴮鶎鷮LWuv~鐛\g@K覐讖(3垚鲱孱鲱鲱遒铞铄铞铄钗铞铄铞铄盥畛篓湪骂憛戭鲱孱鲱孱鲱h馷6丱JQJwh#h馷OJQJwh#h馷5丱JQJwh<h馷OJQJwh<jh馷OJQJUjh馷OJQJUhSJh馷OJQJhSJh馷5丱JQJh馷6丱JQJh馷OJQJh馷5丱JQJ4l*+鑿閺湊潗<=?@駬驌箶簲獣悥憱<=56q & Fgd馷gd馷gd馷 & Fgd馷垚帎瓚箲顟驊魬鴳)/Etu墥晵棐罀菕,1@{啌論釗駬驌)8?珨瓟笖箶簲鞌魯鯏鴶EK鲱孱鲱鲱鲱鲱陬谖陬陬诼陬孱纶钰钰乌钰纶东疃泿浂~h??h馷6丱JQJ^JaJh馷5丱JQJ^JaJheh馷5丱JQJ^JaJheh馷OJQJh馷OJQJ^JaJh靫h馷6丱JQJh靫h馷5丱JQJh靫h馷OJQJh馷5丱JQJh馷OJQJh馷6丱JQJ/KNYnt〞獣睍禃紩繒葧讜跁軙鍟钑魰鲿(y{€彇悥憱葨詵$,;枟疋制只郴郴郴郴郴郴郴郴Щ郴硾謵持€謕謊h稬h馷OJQJh&X=h馷6丱JQJ^JaJh&X=h馷5丱JQJ^JaJh&X=h馷OJQJh3bh馷6丱JQJh3bh馷5丱JQJh馷OJQJh$Y0h馷OJQJh??h馷6丱JQJ^JaJh馷OJQJ^JaJh??h馷OJQJ^JaJhW~h馷OJQJ^JaJ%枟脳藯$)*12367MO軜錁鐦鶚麡Z\br謾鈾Uv仛#蕸箬噼嘣嗤锣栲栲栲蠊噼噼噼嘣喹澀幁~璶h攑?h馷5丱JQJ^JaJh稬h馷6丱JQJ^JaJhbDF炼燌束而棇€寳寳uj鴂鴂h$Wh馷OJQJh5mh莗OJQJh鵙 h莗OJQJh莗h莗5丱JQJh莗h莗OJQJh莗OJQJh顯h馷5丱JQJh顯h馷OJQJh&(h馷OJQJh馷6丱JQJh╧h馷6丱JQJh?h馷OJQJhYbh馷5丱JQJhYbh馷OJQJh馷OJQJ%FNOWYit}菠搐沥绀瑜椁颏鳏&'ST]^ghqr叆惀堀幞浈毳馥偿偿偿偿偿偿偿硹硥硙t}it}h馷H*OJQJ\h馷OJQJ\h5mh馷OJQJ\hh馷6丱JQJ\hh馷5丱JQJ\hh馷H*OJQJ\hh馷OJQJ\hh馷OJQJh莗h莗OJQJh╧h馷6丱JQJh$Wh馷5丱JQJh$Wh馷OJQJh馷OJQJ' "#$./0=>?GHIRST]^_`aemnpr痞铅圈咋枝卅!毀洤蜴垡孥益垡孥益垡孥益垡孥益垡墓災益益益覐弔h5mh馷OJQJh羫h馷5丱JQJ^JaJh羫h馷OJQJ^JaJh5mh馷5丠*OJQJ\h硍h馷OJQJ\h馷5丱JQJ\h5mh馷5丱JQJ\h馷OJQJ\h馷H*OJQJ\h5mh馷OJQJ\h5mh馷H*OJQJ\?毀洤湩围惜妲绉{| !牘々pq姭嫬叕啲嚞宫含刪^刪gd馷 & F橚刪^刪gd馷gd馷gd馷洤湩煣围妲glmpy槰（ .<C崺挬珐惟EGb摢煪陋咧籍鉴著檸鴤鴙鴎鴂鳶hh馷5丱JQJhU'h馷6丱JQJhU'h馷OJQJh稬h馷5丱JQJheh馷6丱JQJh稬h馷OJQJheh馷5丱JQJh馷6丱JQJh馷5丅*OJQJphh馷B*OJQJphh馷6丅*OJQJphh馷5丱JQJh竈h馷5?*OJQJh馷5?*OJQJh馷OJQJ陋讵!*OQuv壂姭か矮搏斋塬浍Skvwz偓儸嚞ガì箅唠噪箅删氩霑箅夒乽l乤侂㏒h腀h馷5?*OJQJh莗h莗OJQJh莗5丱JQJh"h馷6丱JQJh莗OJQJh"h馷5丱JQJh馷6丱JQJhh馷OJQJh馷5丱JQJhh馷5丱JQJh遆4h馷OJQJhC/h馷OJQJh稬h馷OJQJh稬h馷5丱JQJh馷OJQJhF`h馷6丱JQJì┈宫含片犀袁t幁彮懎毉Ν莪 !NTW叜嚠槷ぎ卯赢债弋岙Vklny嚡摨庄氙箨怅赓赓怅馔露峦怅獰摢熲坾坧|堚坾坾坧坾堚赈hxJh馷6丱JQJhxJh馷5丱JQJhxJh馷OJQJh$Y0h馷6丱JQJh$Y0h馷OJQJh$Y0h馷5丱JQJh?Ah馷6丱JQJh?Ah馷OJQJh?Ah馷5丱JQJh馷6丱JQJh馷OJQJh馷5丱JQJh腀h馷5丱JQJ,含櫗毉啴嚠喈岙yz舣醑ef邪寻CDxy壮俪鄢瓿氤gd馷刪^刪gd馷 & F刪^刪gd馷氙懑醑,25JOv儼赴腊喟氚-2Dw偙RYZ懖挷摬\]^鲱鲱弼钯铞铄钔钯盍畲Υ湁zd墇塜h馷OJQJ^JaJ+jdhLh馷OJQJU^JaJhLh馷OJQJ^JaJ%jhLh馷OJQJU^JaJh馷OJQJaJhlh馷5丱JQJaJhLh馷OJQJaJh?Rh馷6丱JQJh?h馷5丱JQJh?h馷6丱JQJh馷6丱JQJh馷OJQJh馷5丱JQJ^jkwxy叧ǔ贸沙殖爻诔鄢瓿龀f 实嗟镟郧江詾幵镌乻乻kbkVkJk>hlx/h馷>*OJQJh?h馷5丱JQJhe{)h馷>*OJQJh馷5丱JQJh馷OJQJhLh馷5丱JQJaJhLh馷OJQJaJhlh馷6丱JQJ^JaJh*OJQJhP8h馷5?*OJQJh馷5?*OJQJh馷OJQJ2曰嗷昊牖旎4Z4y4z4{4??r5s5u5v5x5y5{5|5~5??????????????啉友煟煟煟煐鴪~坥堷ka[a[k h馷0Jjh馷0JUh馷h莗0JOJQJmHnHuh馷0JOJQJjh馷0JOJQJUh馷5丱JQJh=Wjh=WUhvh馷5丱JQJh稃h馷OJQJh稃h馷OJQJ^JaJUh稃h馷5丱JQJhP8h馷5?*OJQJh馷5?*OJQJh馷OJQJ#. Methods for diagnosing acute megakaryocytic leukemia. US Provisional Patent Application 10/880764, published 1/05/2006.Wen, Q, Huang, Z, Stern, A, Gould, R, Bradner, J, and Crispino, JD. Methods for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders. US Patent Application 12/613,996 filed November 6, 2009.  J.D. Crispino Page  PAGE 19 PAGE  September 10, 2012 旎z4{4p5q5r5t5u5w5x5z5{5}5~5?????????????匋&`#$$?a$gd馷 & F刪^刪gd馷????????钽鲞h=Wh"Q-h馷OJQJh馷OJQJh馷 h馷0J???gd馷H 0 000€P:p馷靶/ 班=!盃"?#悹$悁%靶靶 愋Dp|HH(?FG(HH(d'`D猩陏寕K j-crispino@northwestern.edu嗌陏寕K Fmailto:j-crispino@northwestern.eduqD猩陏寕K 嗌陏寕K http://www.ncbi.nlm.nih.gov/pubmed/18174176?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSumD猩陏寕K 嗌陏寕K Xhttp://www.ncbi.nlm.nih.gov/pubmed/22460584OJQJ_HmH nH sH tH <`?< NormalCJ_HmH sH tH T@T  Heading 1$dh@&a$5?*CJOJQJkH'@@@  Heading 2$@& >*OJQJ\@\  Heading 3$$蟒Lhp 剺兀&]剺 >*OJQJ^@^  Heading 4$$蟒Lhp 剺兀&]剺5?丱JQJ\@\  Heading 5$$蟒Lhp 剺兀&]剺 5丱JQJ@@@  Heading 6$@& 5丱JQJDA`?D Default Paragraph FontVi?V 0 Table Normal :V 44 la (k ?(0No List 4 @4 Footer?.)@. Page Number4@4 Header?@Y@"@ Document Map-D OJQJTP@2T Body Text 2$?dh]?齛$5丅*OJQJPB@BP Body Text蟒Lp 剺剺OJQJF>@RF Title$p@&a$ 5丱JQJDQ@bD Body Text 35?*CJ OJQJ@&`?q@ Footnote ReferenceH*dS@d Body Text Indent 3$勫d]`勫a$OJQJP?P HTML Body 7$8$H$OJQJ_HmH sH tH H0@H List Bullet & F7$8$OJQJ6U`?6 聾6 Hyperlink >*B*phPK!涜pO[Content_Types].xml瑧薺?E鲄卸豶?ヘ微廬嬼yl嬝#!MB蝼;.卬姨谨台\艫?&绌耀夹 生芉W橄蚄v疷bOX?&疆释1`RⅵT闉9<搇?ぼ$┐>幚r崫 `沸」-夳c=1g嗟瘕青^,?彿阗?q€;湷^?4髑槿?Wq{n阍塷g淎撙>曧?f??<")QH裤麆xK┟梶ㄐ]奪榸)橛亾MS欯\&>!7;wP?熥[淅EBU`?綩楥? j<J< CNVmmp-.<矪糓0d媠駘W垚K枟蕸盁F洤陋ì氙^嗟曰??^dkruw| =??Q*..1+5??w:w;更6B覨絆蠺[嘺i閘'q磚袀lq毀含氤旎??_`abcefghijlmnopqstvxyz{}~€齺妭戋#悫jX€X?晫X?晞+25CJp!晙!?@€€€饞??  養 S  ?=C.4( . r x !!W!]!????2"6"z"~"???????)????/-7->-G-H-P-k-q-y-|-??=.D.7/D瑐硞穫膫詡趥陚飩虄趦爡KQ]crz拞潌珕硢脝藛趩釂騿鲉貒鄧(0鲌麍攭殙\cov{儖螌諏賹鐚雽鰧鷮泹爫瑣皪睄祶駦鯈鷯 CNSX]h儙妿,3:`f彁攼睉窇紤膽蓱螒詰趹邞閼湐茢虜褦跀$EMio槙潟珪貢迺飼魰瑮簵織脳袟詶跅迼鏃陾饤 3:LVZcgnry彉殬灅瓨硺窐綐翗蓸蹣錁魳麡y倷ER艢蕷蠚讱仜姏瑳硾窙繘覜貨ir}儨憸枩洔艤藴y}仭尅槨潯!仱hl07;ANTX^bnr{埀彠钵魔骚舁$bf酮侏偒壂!'.IQDJPUnx碑划廉犬t|òhk韅鯼zh€hEIhk::::濫 ` Uy虌Z?o&缧?-9/巼槓7Z騨S駂?尟磪.O???*X5v靈[,?;4j?=2u;誋?=,z@-?$qX)?[RAH?,=鸕誋?yS v?wT篧 吚"Yu甗vN0<痎l!跅gr]浏除xg鞠F肙舗,http://www.ncbi.nlm.nih.gov/pubmed/22460584Zv€http://www.ncbi.nlm.nih.gov/pubmed/18174176?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum=X#mailto:j-crispino@northwestern.edu  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€??????????Root Entry F軄矄洦€Data 1Table,nWordDocument劈SummaryInformation(DocumentSummaryInformation8CompObj`?? F Microsoft Word 97-2004 Document?NB6WWord.Document.8